Background: The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II).
Aims: To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy.
Methods: A randomised 24-week double-blind placebo-controlled trial of tiotropium 18 μg once daily (via HandiHaler) was performed in maintenance therapy-naive patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 and post-bronchodilator FEV1 ≥50 and <80%.
Results: A total of 457 patients were randomised (238 tiotropium, 219 placebo; mean age 62 years; FEV1 1.93 l (66% predicted)). Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3 h (AUC0-3h) at week 24 (primary endpoint): 0.19 vs. -0.03 l (least-squares mean difference 0.23 l, P<0.001). FVC AUC0-3h, trough and peak FEV1 and FVC were significantly improved with tiotropium versus placebo (P<0.001). Compared with placebo, tiotropium provided numerical improvements in physical activity (P=NS). Physician's Global Assessment (health status) improved (P=0.045) with less impairment on the Work Productivity and Activity Impairment questionnaire (P=0.043) at week 24. The incidence of exacerbations, cough, bronchitis and dyspnoea was lower with tiotropium than placebo.
Conclusions: Tiotropium improved lung function and patient-reported outcomes in maintenance therapy-naive patients with GOLD stage II COPD, suggesting benefits in initiating maintenance therapy early.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373257 | PMC |
| http://dx.doi.org/10.1038/npjpcrm.2014.3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SLC27A3 downregulation restores Th17/Treg balance and alleviates COPD via JAK2/STAT3 pathway inhibition.
Allergol Immunopathol (Madr)
January 2025
Department of Geriatric Medicine, Qinghai University Affiliated Hospital, Xining, Qinghai, China.
The main goal of this investigation is to find out how solute carrier family 27 member 3 (SLC27A3) is expressed in the lung tissue of mice with chronic obstructive pulmonary disease (COPD), and how it relates to lung function. A model of COPD was established by exposing organisms to cigarette smoke, followed by investigating the role of SLC27A3 in COPD through experiments conducted both in living organisms and in laboratory settings. Knockout mice lacking SLC27A3 were produced through siRNA transfection to investigate lung function and inflammatory response, using methods such as hematoxylin-eosin staining and enzyme-linked immunosorbent assay.
View Article and Find Full Text PDFLow-carbohydrate diet score and chronic obstructive pulmonary disease: a machine learning analysis of NHANES data.
Front Nutr
December 2024
Department of Intensive Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, The Third Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Changzhou, China.
Background: Recent research has identified the Low-Carbohydrate Diet (LCD) score as a novel biomarker, with studies showing that LCDs can reduce carbon dioxide retention, potentially improving lung function. While the link between the LCD score and chronic obstructive pulmonary disease (COPD) has been explored, its relevance in the US population remains uncertain. This study aims to explore the association between the LCD score and the likelihood of COPD prevalence in this population.
View Article and Find Full Text PDFMachine Learning for Enhanced COPD Diagnosis: A Comparative Analysis of Classification Algorithms.
Diagnostics (Basel)
December 2024
Computer Science Department, Taif University, Taif 21944, Saudi Arabia.
: In the United States, chronic obstructive pulmonary disease (COPD) is a significant cause of mortality. As far as we know, it is a chronic, inflammatory lung condition that cuts off airflow to the lungs. Many symptoms have been reported for such a disease: breathing problems, coughing, wheezing, and mucus production.
View Article and Find Full Text PDFSingle-Inhaler Triple vs LABA-ICS Therapy for COPD: Comparative Safety in Real-World Clinical Practice.
Chest
October 2024
Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital; Montreal, QC; Medicine, McGill University, Montreal, QC, Canada.
Article Synopsis
- Recent treatment guidelines for COPD now recommend single-inhaler triple therapy (LAMA-LABA-ICS) over the LABA-ICS combination, but studies show higher cardiovascular risks with the triple therapy.
- A study using UK patient data from 2017-2021 compared COPD patients on triple therapy to those on LABA-ICS, finding that triple therapy was linked to a higher incidence of major adverse cardiovascular events (MACE), particularly within the first four months.
- The study reported that the adjusted hazard ratio for MACE with triple therapy was 1.28, and for all-cause mortality, it was 1.31, indicating a notable increase in risks compared to LABA
Long-acting muscarinic antagonist and long-acting β-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review.
Ther Adv Respir Dis
October 2024
Primary Care Respiratory Group, Winnsboro, SC, USA.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Faster lung function impairment occurs earlier in the disease, particularly in mild-to-moderate COPD, highlighting the need for early and effective targeted interventions. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 report recommends initial pharmacologic treatment with a long-acting muscarinic antagonist (LAMA) and long-acting β-agonist (LABA) combination in group B (0 or 1 moderate exacerbation not leading to hospitalization, modified Medical Research Council score of ⩾2, and COPD Assessment Test™ score of ⩾10) and E (⩾2 moderate exacerbations or ⩾1 exacerbation leading to hospitalization and blood eosinophil count <300 cells/µL) patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!